Association of Apolipoprotein-A, B and Trans Fatty Acids With Cardiovascular Events: Isfahan Cohort Study



Sarrafzadegan N¹ ; Asgari S² ; Toghianifar N³ ; Talaei M⁴ ; Tavassoli A⁵ ; Boshtam M⁶ ; Sadeghi M⁷
Source: Journal of Isfahan Medical School Published:2011

Abstract

Background: Various studies have shown that the risk of apolipoprotein-A (apo-A), B (apo-B), and trans fatty acids may be different for cardiovascular disease (CVD) events in different populations. This study aimed to estimate the relative risk of apo-A, apo-B, and trans fatty acids for the occurrence of cardiovascular disease events in a cohort study. Methods: A cohort study was performed on 5375 subjects aged ≥ 35 years old participating in the Isfahan Healthy Heart Program (IHHP) that had been recruited with multistage cluster random sampling method. Apo-A and apo-B were measured in all subjects while trans fatty acids were measured on a random sample of 238 subjects. The relative risk of these factors for CVD events was defined in a 6-year period. T-test was used to compare means. Logistic regression and Cox regression were used to calculate Hazard ratio of cardiovascular disease events. Finding: After adjustment for age and sex, the relative risk for cardiovascular disease events was 2.393 (95%CI 1.155-4.961) for apo-B/A, 1.007 (95%CI 1.004-1.009) for total cholesterol, 1.002 (95%CI 1.001-1.003) for triglycerides, and 1.008 (95%CI 1.005-1.010) for LDL-cholesterol. After adjustment for smoking, diabetes, hypertension, and obesity, the relative risk for total cholesterol (1.006, 95%CI 1.003-1.008) and LDL-cholesterol 1.007, 95%CI 1.004-1.010) was significant while insignificant for trans fatty acids. Conclusion: This study showed that relative risk of apo-B/A for cardiovascular disease events is similar to total cholesterol and LDL-cholesterol. However, after adjustment for other risk factors, the association remained significant only for total cholesterol and LDL-cholesterol. Trans fatty acids did not show significant risk for ardiovascular disease event.